Ensuring vaccine safety in immunization programmes - A WHO perspective

Vaccine

Volumn 19, Issue 13-14, 2001, Pages 1594-1605

  Jodar, L ^a   Duclos, P ^a   Milstien, J B ^a   Griffiths, E ^a   Aguado, M T ^a   Clements, C J ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Adverse events; Immunization programmes; Vaccine delivery systems; Vaccine safety

Indexed keywords

VACCINE;

DRUG DELIVERY SYSTEM; DRUG SAFETY; HUMAN; IMMUNIZATION; MEDICAL TECHNOLOGY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STAFF TRAINING; WORLD HEALTH ORGANIZATION;

EID: 0035825603     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00358-3     Document Type: Article

References (88)

1. Vaccine safety concerns everyone
2. Safe administration of vaccines
3. Unsafe injections in the developing world and transmission of blood-borne pathogens: A review
4. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: Model-based regional estimates
5. Acquired immunodeficiency syndrome in Romania
6. Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors
7. Prevalence, impact and risk factors of hepatitis C infection
8. Epidemiology of needlestick injuries in house officers
9. Underreporting of needlestick injuries in a university hospital
10. Epidemiology of hospitalsharps injuries: A 14-year prospective study in the pre-AIDS and AIDS eras
11. Thiomersal in vaccines. Correspondence
12. Thiomersal as a vaccine preservative
13. Measles vaccination in India and controversies regarding adverse reactions
14. Toxic shock syndrome: An unforseen complication following measles vaccination
15. Vaccine supply and quality. Surveillance of adverse events following immunization
16. Occurrence of suppurative lymphadenitis after a change of BCG vaccine
17. BCG associated adenitis
18. Outbreak of Bacillus Calmette-Guérin associated lymphadenitis and abscesses in Jamaican children
19. The epidemiology of measles
20. Measles vaccines, a review of adverse events
21. Diphtheria-tetanus-pertussis immunization and sudden infant death: Results of the National Institute of Child Health and Human Development Co-operative Epidemiological Study of Sudden Infant Death Syndrome Risk Factors
22. Safety, effectiveness and ease of use of a non-reusable syringe in a developing country
23. Use of SoloShot auto-destruct syringes compared with disposable syringes, in a national immunization campaign in Indonesia
24. Auto-disable syringes for immunization: Issues in technology transfer
25. The use of multi-dose vaccine vials in subsequent immunization sessions
26. Development and clinical application of new polyvalent combined paediatric vaccines
27. Combination vaccines: Opportunity or recipe for chaos?
28. Fostering for DTP and DTP-based combination vaccines
29. Combination vaccines consisting of acellular pertussis vaccines
30. Pulsed controlled-released system for potential use in vaccine delivery
31. Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro
32. Estimation of antigenic tetanus toxoid extracted from biodegradable microspheres
33. Modulation of the immune response to tetanus toxoid by polylactide-polyglycolide microspheres
34. The development of a tetanus controlled release vaccine
35. An outbreak of hepatitis B associated with jet injections at a weight reduction clinic
36. Revolutionising immunisation
37. Injectable solid vaccines: A role in future immunization?
38. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
39. Basic mechanisms of mucosal immunity - A major adaptive defence system
40. Typhoid fever vaccines
41. A review of the current status of enteric vaccines
42. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
43. Withdrawal of rotavirus vaccine recommendation
44. Immunopotentiation, adjuvants, nonliving antigen delivery systems and naked DNA vaccines
45. Immunogenicity of new virosome influenza vaccine in elderly people
46. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization
47. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens
48. Vaccine developments
49. DNA vaccines. Mechanisms for generation of immune responses
50. Expression of hepatitis B surface antigen in transgenic plants
51. Immunogenicity of transgenic plant-derived hepatitis B surface antigen
52. Oral immunization with a recombinant bacterial antigen produced in transgenic plants
53. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice
54. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): Potatoes expressing a synthetic LT-B gene
55. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
56. Novel adjuvants currently in clinical testing November 2-4, 1998, Fondation Merieux, Annecy, France: A meeting sponsored by the World Health Organization
57. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
58. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit
59. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines
60. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants
61. Effect of small bowel bacteria overgrowth on the immune of single-dose live oral cholera vaccine CVD 103-HgR
62. Optimism over vaccines administered via mucosal surfaces
63. Skin immunization made possible by cholera toxin
64. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
65. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates
66. Contamination of poliovirus vaccine with SV40 and the incidence of medulloblastoma
67. Requirements for oral poliomyelitis vaccine
68. Examination of poliovirus vaccine preparations for SV40 sequences
69. Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement
70. Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines
71. Reverse transcriptase activity in chicken-cell derived vaccine. WHO Consultation, April 1998
72. Developing a national system for dealing with adverse events following immunization
73. Surveillance of adverse events following immunization
74. Vaccine adverse events: Causal or coincidental?
75. Autism, inflammatory bowel disease and MMR vaccine
76. No evidence for measles, mumps and rubella-associated inflammatory bowel disease or autism in a 14 year prospective study
77. Vaccine safety